• Corpus ID: 1774712

Transcatheter Closure of Atrial Septal Defects

  title={Transcatheter Closure of Atrial Septal Defects},
  author={Victor-Xavier Tadros and Anita W. Asgar},
A trial septal defects (ASDs) are one of the most common congenital heart defects, with a prevalence estimated to affect 100 of 100,000 live births.1 ASDs are classified according to location, the most frequent being secundum ASD (75%–80%), primum ASD (15%–20%), sinus venosus (5%–10%), and the less common defect, coronary sinus (< 1%). These defects frequently result in left-to-right shunting. Current indications for closure, according to American and European guidelines, are a ratio of… 

Figures and Tables from this paper

Long-term Complications After Transcatheter Atrial Septal Defect Closure: A Review of the Medical Literature.

Comparison of Figulla Flex® and Amplatzer™ devices for atrial septal defect closure: A meta-analysis.

No differences exist regarding procedural success between the ASO and FSO devices but the last was associated to shorter procedure time, less radiation, and lower rate of supraventricular arrhythmias in follow-up.

Efficacy and safety of transcatheter closure in adults with large or small atrial septal defects

Transcatheter closure in this cohort of patients with large or small ASD was effective with similar complication rates during short-term follow-up irrespective of the size of the implanted device.

Spontaneous Resolution of Residual Shunting in 2 Compromised Patients after Amplatzer Occlusion of Postinfarction Ventricular Septal Defects.

It is thought that even substantial shunting in the presence of severe heart failure or hemolysis can eventually resolve spontaneously, assuming effective management of the concomitant medical conditions.

Safety and efficacy of the Amplatzer septal occluder: A systematic review and meta-analysis.

Historical developments of atrial septal defect closure devices: what we learn from the past

In this review, the historical development of ASD devices in design, material and technique with clinical data is presented, and the future perspectives in percutaneous ASD closures are provided.

A retrospective study: elevation of cardiac troponin T after transcatheter closure of the interatrial septum is related to device size and procedural duration

The findings indicate that mechanical trauma caused by inserting the ASD device may play an important role in this elevation of cardiac troponin T, indicating a minor and clinically insignificant myocardial injury.

Endocarditis and Incomplete Endothelialization 12 Years after Amplatzer Septal Occluder Deployment.

The need for further investigation into prosthetic device endothelialization, endocarditis prophylaxis, and recommended levels of physical activity in patients whose devices might be incompletely endothelialized is reinforced.

Initial clinical experience with the GORE septal occluder for the treatment of atrial septal defects and patent foramen ovale.

    X. FreixaR. Ibrahim A. Asgar
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
  • 2013
This initial experience with the new GSO device has demonstrated acceptable safety with no procedural complications and acceptable efficacy with low rates of residual shunting at three-month follow-up.

Eight-French intracardiac echocardiography – safe and effective guidance for transcatheter closure in atrial septal defects –.

ICE-guided ASD occlusion with ASO is safe and effective and provides accurate anatomical information, sufficient to perform the procedure, and there were benefits of avoidance of general anesthesia, and shorter procedure time.

Feasibility and safety of a new generation of gore septal occluder device in children

The new GORE Septal Occluder device appears to be a feasible, well-tolerated and successful tool for the closure of an ASD of 15 mm or less in childhood.

Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: Review of registry of complications and recommendations to minimize future risk

The risk of device erosion with ASO is low and complications can be decreased by identifying high‐risk patients and following them closely, as well as identifying high-risk cases, early recognition, and prompt intervention.

Comparison of the Occlutech® Figulla® Septal Occluder and Amplatzer® Septal Occluder for Atrial Septal Defect Device Closure

Both devices were safe and effective for percutaneous ASD closures and the OFSO had the benefit of a shorter fluoroscopic time.